Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | CNR1 | P21554 | 13/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenabasum SCHEMBL29872156 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056887 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL26441 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056881 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL17414503 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL13035015 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL23202520 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL29362927 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL29611496 | 0.99 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL14501182 | 0.99 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | claimed |
| US-20050080083-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-04-14 | — | — | US | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| WO-2004060366-A1 | A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040067992-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040006100-A1 | Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S) | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067992-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia | CA2, CA1, CA4 | CNR2 128/4885CNR1 569/4885GLRA1 2610/4885 |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | CNR2 603/4885CNR1 1320/4885GLRA1 2352/4885 |
| US-20040006100-A1 | Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (COX 2) inhibitor(S) | PTGS2, PTGES2, PTGS1 | CNR2 492/4885CNR1 1413/4885GLRA1 1806/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | CNR2 307/4885CNR1 834/4885GLRA1 3928/4885 |
| US-20050080083-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage | AGTR2, AGTR1, ACE2 | CNR2 34/4885CNR1 93/4885GLRA1 278/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | CNR2 35/4885CNR1 273/4885GLRA1 3325/4885 |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | APP, BACE2, PTGS2 | CNR2 240/4885CNR1 1259/4885GLRA1 2265/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | CNR2 1113/4885CNR1 1914/4885GLRA1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.